Kavita M Reddy, MD
Internal Medicine · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Reddy’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A52830 · Current
Licensed to practise in California · since 1994 · expires 2027-04-30 · University of Madras, Madras Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$38,790
Medicare paid this office $38,790 for 284 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 181 | $21,090 | $109 |
| New patient visit (45+ min) | 54 | $6,952 | $129 |
| Short return visit (20+ min) | 34 | $2,820 | $81 |
| New patient visit (30+ min) | 23 | $2,250 | $98 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 11 | $553 | $50 |
See all 7 services
| Return visit (30+ min) | 181 | $21,090 | $109 |
| New patient visit (45+ min) | 54 | $6,952 | $129 |
| Short return visit (20+ min) | 34 | $2,820 | $81 |
| New patient visit (30+ min) | 23 | $2,250 | $98 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 11 | $553 | $50 |
| Injection of drug or substance under skin or into muscle | 17 | $230 | $11 |
| Urinalysis, manual test | 38 | $130 | $3 |
Who their Medicare patients are
284 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 17% · Women 64% · Also on Medicaid 12% · Health risk score 0.89. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 66% · Diabetes 20% · Coronary heart disease 17% · Chronic kidney disease 16% · Atrial fibrillation 16% · Cancer 15% · Depression 13% · Heart failure 8% · COPD 7% · Dementia 7% · Stroke 7%.
The office billed $142,600, Medicare allowed $54,357 and paid $38,790; for 554 services of 43 kinds; $163 of it was for drugs given in the office and $38,627 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 284 | 554 | 76 | 0.89 | $142,600 | $38,790 |
| 2023 | 358 | 645 | 77 | 0.93 | $167,048 | $48,963 |
| 2022 | 342 | 625 | 77 | 0.95 | $133,738 | $41,149 |
| 2021 | 327 | 607 | 76 | 1.03 | $128,455 | $40,372 |
| 2020 | 241 | 449 | 78 | 1.17 | $88,896 | $22,940 |
| 2019 | 405 | 822 | 76 | 1.09 | $164,474 | $42,670 |
| 2018 | 381 | 824 | 76 | 1.02 | $142,146 | $39,097 |
| 2017 | 376 | 747 | 77 | 1.19 | $129,636 | $34,499 |
| 2016 | 132 | 239 | 75 | 1.32 | $64,443 | $19,310 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 244 | $28,296 | $112 |
| New patient visit (45+ min) | 71 | $9,465 | $133 |
| Short return visit (20+ min) | 24 | $2,006 | $84 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 38 | $1,911 | $50 |
| New patient visit (30+ min) | 12 | $1,204 | $100 |
| Injection of drug or substance under skin or into muscle | 18 | $283 | $13 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 16 | $259 | $16 |
| Urinalysis, manual test | 36 | $126 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 15 | $28 | None |
2022: 10 services
| Return visit (30+ min) | 190 | $22,134 | $113 |
| Short return visit (20+ min) | 66 | $5,680 | $82 |
| New patient visit (45+ min) | 14 | $2,154 | $154 |
| Short return visit | 35 | $1,819 | $49 |
| New patient visit (15+ min) | 30 | $1,643 | $55 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 29 | $1,462 | $50 |
| New patient visit (30+ min) | 14 | $1,409 | $101 |
| Injection of drug or substance under skin or into muscle | 23 | $330 | $14 |
| Urinalysis, manual test | 44 | $152 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 14 | $22 | None |
2021: 7 services
| Return visit (30+ min) | 210 | $25,521 | $117 |
| Short return visit (20+ min) | 77 | $6,131 | $77 |
| New patient visit (30+ min) | 27 | $2,131 | $79 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 31 | $1,642 | $51 |
| Injection of drug or substance under skin or into muscle | 19 | $316 | $14 |
| Urinalysis, manual test | 56 | $198 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $23 | None |
2020: 6 services
| Return visit (30+ min) | 162 | $14,643 | $89 |
| New patient visit (30+ min) | 34 | $3,011 | $89 |
| Short return visit (20+ min) | 48 | $2,644 | $55 |
| Injection of drug or substance under skin or into muscle | 20 | $296 | $13 |
| Urinalysis, manual test | 22 | $76 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $23 | None |
2019: 9 services
| Return visit (30+ min) | 305 | $28,873 | $91 |
| Short return visit (20+ min) | 73 | $4,790 | $62 |
| New patient visit (30+ min) | 33 | $2,582 | $78 |
| Application of nonmoveable forearm to hand splint | 11 | $753 | $68 |
| Injection of drug or substance under skin or into muscle | 38 | $610 | $15 |
| Urinalysis, manual test | 46 | $160 | $3 |
| Insertion of needle into vein for collection of blood sample | 24 | $71 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 23 | $45 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $23 | None |
2018: 9 services
| Return visit (30+ min) | 209 | $20,379 | $94 |
| Short return visit (20+ min) | 161 | $9,421 | $56 |
| New patient visit (30+ min) | 17 | $1,524 | $90 |
| Injection of drug or substance under skin or into muscle | 33 | $741 | $21 |
| Inhalation treatment for airway obstruction or sputum production | 11 | $200 | $18 |
| Urinalysis, manual test | 36 | $126 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 26 | $59 | None |
| Infusion, normal saline solution , 1000 cc | 17 | $26 | None |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 11 | $1 | None |
2017: 11 services
| Return visit (30+ min) | 228 | $19,407 | $84 |
| Short return visit (20+ min) | 133 | $8,578 | $61 |
| New patient visit (30+ min) | 13 | $1,115 | $86 |
| Injection of drug or substance under skin or into muscle | 27 | $697 | $24 |
| Inhalation treatment for airway obstruction or sputum production | 21 | $410 | $20 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 11 | $137 | $12 |
| Automated urinalysis test | 21 | $63 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 17 | $38 | None |
| Urinalysis, manual test | 11 | $38 | $3 |
| Infusion, normal saline solution , 1000 cc | 23 | $33 | None |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 19 | $2 | None |
2016: 3 services
| Return visit (30+ min) | 79 | $7,322 | $93 |
| Short return visit (20+ min) | 47 | $3,471 | $68 |
| Injection of drug or substance under skin or into muscle | 13 | $339 | $24 |
Drugs they prescribed that Part D paid
$3,823
Pharmacies billed $3,823 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
157 generic and fewer than 11 brand-name prescriptions · $3,823 in drug cost · 71 antibiotic prescriptions to 61 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Albuterol Sulfate Hfa | 23 | $555 | $24 |
| Fluticasone Propionate | 11 | $236 | $21 |
| Cefuroxime | 11 | $108 | $10 |
| Amoxicillin-Clavulanate Potass | 13 | $86 | $7 |
Year by year
| 2024 | 197 | 130 | None | None | $3,823 |
| 2023 | 250 | 184 | None | 14% | $4,942 |
| 2022 | 185 | 141 | None | 9% | $2,542 |
| 2021 | 149 | 123 | None | 9% | $2,054 |
| 2020 | 129 | 96 | None | 14% | $2,399 |
| 2019 | 222 | 166 | None | 24% | $5,664 |
| 2018 | 195 | 156 | None | None | $4,497 |
| 2017 | 245 | 182 | 6% (14) | None | $4,735 |
| 2016 | 96 | 72 | None | None | $2,387 |
| 2014 | 16 | None | None | None | $466 |
| 2013 | 47 | 20 | None | None | $1,469 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Albuterol Sulfate Hfa | 24 | $685 | $29 |
| Cefuroxime | 25 | $428 | $17 |
| Nitrofurantoin Mono-Macro | 14 | $259 | $18 |
| Paxlovid (Eua) | 19 | $197 | $10 |
| Fluticasone Propionate | 15 | $150 | $10 |
| Amoxicillin-Clavulanate Potass | 19 | $147 | $8 |
2022: 2 drugs
| Nitrofurantoin Mono-Macro | 16 | $421 | $26 |
| Paxlovid (Eua) | 15 | $138 | $9 |
2021: 3 drugs
| Nitrofurantoin Mono-Macro | 20 | $342 | $17 |
| Cephalexin | 23 | $209 | $9 |
| Prednisone | 12 | $33 | $3 |
2020: 1 drug
| Cephalexin | 15 | $106 | $7 |
2019: 6 drugs
| Ventolin Hfa | 16 | $911 | $57 |
| Albuterol Sulfate Hfa | 11 | $529 | $48 |
| Cephalexin | 29 | $268 | $9 |
| Nitrofurantoin Mono-Macro | 11 | $247 | $22 |
| Fluticasone Propionate | 11 | $119 | $11 |
| Amoxicillin-Clavulanate Potass | 11 | $110 | $10 |
2018: 2 drugs
| Cephalexin | 38 | $352 | $9 |
| Nitrofurantoin Mono-Macro | 14 | $278 | $20 |
2017: 7 drugs
| Proair Hfa | 17 | $967 | $57 |
| Nitrofurantoin Mono-Macro | 11 | $263 | $24 |
| Cephalexin | 28 | $239 | $9 |
| Levofloxacin | 19 | $236 | $12 |
| Naproxen | 19 | $83 | $4 |
| Prednisone | 11 | $44 | $4 |
| Tramadol | 11 | $30 | $3 |
2016: 1 drug
| Nitrofurantoin Mono-Macro | 13 | $368 | $28 |
Money from drug and device companies
$12 in 2021
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $12 | 1 payment
|
See the published payment
| AstraZeneca Pharmaceuticals LP | Meals · 2021-04-14 | Lynparza | $12 |
Professional record
- NPI
- 1427136019
- Licence
- CA A52830California A52830: Current · expires 2027-04-30
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A528300
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 2350 W. El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2006-11-01
- NPI last updated
- 2016-10-11
This is when the NPI record was last certified, not a medical board exam.